rethinkPeptides Search
Menu
Research citation

Targeted deletion of PAC1 receptors in retinal neurons enhances neuron loss and axonopathy in a model of multiple sclerosis and optic neuritis.

AnimalStrong evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

What the researchers found

Neuronal PAC1 receptor deletion caused retinal neuron loss at baseline and increased neuron death and optic nerve damage in EAE, proving cell-autonomous neuroprotection by PACAP.

Why it matters

MS treatments control inflammation but do not stop neurons from dying. PACAP's direct neuron protection could fill this gap.

The numbers in context

PAC1 deletion reduced RGN count at baseline; increased EAE neuron loss; increased optic nerve axonopathy; increased microglia/macrophage presence

How the study worked

Animal study. Used AAV2 to deliver Cre recombinase to retinal neurons of floxed PAC1 mice. Subjected to EAE (MS model). Measured retinal ganglion cell counts, dendrites, optic nerve pathology, and microglia presence.

Who was studied

Mice with retinal neuron-specific PAC1 receptor deletion subjected to EAE

What this study cannot tell us

Mouse model. EAE does not perfectly replicate human MS. Only retinal neurons were studied. Other neuron types may respond differently.

Read the original research

Targeted deletion of PAC1 receptors in retinal neurons enhances neuron loss and axonopathy in a model of multiple sclerosis and optic neuritis.

Neurobiology of disease, 160, 105524

Citation

Van, Christina; Condro, Michael C; Ko, Henly H; Hoang, Anh Q; Zhu, Ruoyan; Lov, Kenny; Ricaflanca, Patrick T; Diep, Anna L; Nguyen, Nhat N M; Lipshutz, Gerald S; MacKenzie-Graham, Allan; Waschek, James A. (2021). Targeted deletion of PAC1 receptors in retinal neurons enhances neuron loss and axonopathy in a model of multiple sclerosis and optic neuritis.. Neurobiology of disease, 160, 105524. https://doi.org/10.1016/j.nbd.2021.105524